| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| General and administrative costs | 213,658 | 221,127 | ||
| Loss from operations | -213,658 | -221,127 | ||
| Dividends and interest earned on marketable securities held in trust account | 1,873,780 | 1,844,469 | ||
| Total other income (expense), net | 1,873,780 | 1,844,469 | ||
| Net income (loss) | 1,660,122 | 1,623,342 | ||
| Earnings per share, basic | 0.08 | - | ||
| Earnings per share, diluted | 0.08 | - | ||
| Weighted average number of shares outstanding, basic | 17,250,000 | - | ||
| Weighted average number of shares outstanding, diluted | 17,250,000 | - | ||
Translational Development Acquisition Corp. (TDACU)
Translational Development Acquisition Corp. (TDACU)